i-Base home
Search Menu
  • Home
  • HTB
  • 2019
  • October

HTB

October 2019

Contents

Editorial

  • HTB 18 October 2019 online

Conference reports

  • IDWeek (2019), 2–6 October 2019, Washington DC
  • HIV suppression and safety with ibalizumab at 48 weeks in expanded access
  • Oral cabotegravir and rilpivirine is durable for 5.5 years in LATTE study
  • Dolutegravir plus rilpivirine had good virologic, safety record in clinics before single tablet available
  • Switching from TDF to TAF linked to higher BMI and cardio risk
  • Possible higher diabetes risk with raltegravir or PIs than NNRTIs
  • Fostemsavir interaction study flags strong CYP3A inducers, statins, oral contraceptives
  • Over half of mostly black US HIV group has NAFLD – and many have NASH
  • People taking more medications and women have higher fall risk in older HIV group
  • No link between raltegravir and adverse birth outcomes in analysis in 2550 women
  • PrEP linked to lower HIV incidence in US, independent of TasP

Antiretrovirals

  • Dual dolutegravir/lamivudine submitted to US FDA as switch option

Treatment access

  • UK contributes £1.4 billion towards Global Fund for 2020 to 2022
  • Global Fund raises US$14 billion for 2020 to 2022

Guidelines

  • NHS England best practice in HIV prescribing and multidisciplinary teams

HIV prevention and transmission

  • US approves F/TAF for PrEP (Descovy): indication excludes risk from receptive vaginal sex

Basic science and immunology

  • Science journal retracts article linking CCR5 deletion to reduced life expectancy

PDFs

  • 18 October 2019 vol 20 no 12
  • HTB RSS

Early access

  • Zero transmission in France for mothers on ART from conception with undetectable viral load at delivery 30 January 2023
  • 56 Dean Street as a nurse-led PrEP clinic: >20,000 clients in 2021 27 January 2023
  • Phase 3 Mosaico HIV vaccine efficacy trial stopped early due to lack of benefit 27 January 2023
  • All early access reports

Current issues

  • January 2023
  • December 2022
  • October 2022
  • Back issues

Special report

  • Latest statistics on HIV in the UK: data for 2021 1 December 2022

More from HTB

  • Conference reports
  • Conference shortcuts
  • Articles by subject
  • PDFs
  • Subscribe
  • HTB homepage

Home

  • i-Base homepage

This website sets no cookies from us or anyone else.

Information on this website is provided by treatment advocates and offered as a guide only. Decisions about your treatment should always be taken in consultation with your doctor.

HIV i-BASE
About us - Contact - Cookies and privacy - Copyright waiver - Terms of use - Home
107 The Maltings, 169 Tower Bridge Road, London SE1 3LJ.
Tel + 44 (0) 208 616 2210. Email admin@i-base.org.uk
Registered charity no: 1081905. Company reg no: 3962064.

Search i-Base

Site navigation

Quick links
HIV positive
Advocate
Professional
Donate
Feedback
Advice and information
Q and A
Phoneline
Pocket info
Guides
HIV meds
Glossary
Research and conference reports
HTB
HTB South
Pipeline report
Publications and resources
Publications
Other resources
Translations
Slide sets
Order and subscribe
News and updates
News
Blogs
Advocates' network
UK-CAB
Training manual
i-Base
About us
Contact
Sitemap
Home
Find us on Facebook
i-Base on Facebook